Back to Products
CJC-1295+Ipamorelin
LOT: SYN-25-98381-B

CJC-1295+Ipamorelin

CJC-1295 without DAC (also known as Modified GRF 1-29) is a short-acting Growth Hormone-Releasing Hormone (GHRH) analog optimized for a half-life of approximately 30 minutes. It mimics the action of endogenous GHRH by stimulating pituitary somatotroph cells to release growth hormone. Unlike the DAC version, it does not bind to circulating albumin, allowing it to preserve the body's natural, pulsatile GH release without causing a continuous growth hormone "bleed". Because it clears the system rapidly, it requires more frequent administration (often daily). Its highly precise, physiological effect makes it a valuable research tool for studying GH axis biology, aging, and body composition. Ipamorelin is a pentapeptide GH secretagogue (sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed as the first selective growth hormone secretagogue, designed to achieve potent GH release without the non-selective pituitary hormone stimulation seen with earlier GHRP compounds. It activates the ghrelin receptor (GHS-R1a) to stimulate pituitary GH release with a potency comparable to GHRP-6 but with significantly lower plasma clearance and minimal impact on cortisol and prolactin. Research has demonstrated its ability to counteract glucocorticoid-induced muscle and bone loss, support recovery processes, and work synergistically with GHRH analogs like CJC-1295.

Research Benefits

  • Produces sustained dose-dependent GH increases (2–10 fold) lasting up to 6 days per injection in human research studies
  • Elevates IGF-1 levels (1.5–3 fold) for up to 28 days with multiple doses, supporting sustained anabolic and recovery signaling in research models
  • Maintains natural GH pulsatility while markedly increasing basal GH trough levels, providing a physiologically coherent GH stimulation profile
  • Activates ghrelin receptor (GHS-R1a) to stimulate pituitary GH release with potency comparable to GHRP-6 and minimal cortisol/prolactin impact
  • Demonstrates synergistic GH release when combined with GHRH analogs, supporting complementary mechanisms in growth hormone axis research
  • Counteracts glucocorticoid-induced decreases in bone formation and muscle strength in preclinical models, supporting recovery and tissue maintenance research

Size

Quantity

Total Price$74.74
CJC-1295 is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH) composed of a modified 36-amino acid sequence. It was developed with Drug Affinity Complex (DAC) technology that enables covalent binding to circulating albumin, dramatically extending its effective half-life from minutes (native GHRH) to 5.8–8.1 days. Since its development, CJC-1295 has been studied in controlled clinical and preclinical settings for its potential influence on growth hormone axis regulation, IGF-1 production, body composition, and metabolic function. Ipamorelin Ipamorelin is a synthetic pentapeptide growth hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, developed by Novo Nordisk as the first receptor-selective GH secretagogue. It was identified within a major medicinal chemistry program aimed at developing GH-releasing compounds with improved selectivity over earlier peptides such as GHRP-6. Since its characterization in 1998, ipamorelin has been studied in controlled experimental settings for its potential influence on pituitary GH secretion, growth hormone axis biology, body composition, and bone and muscle metabolism.